Drug Profile
C 012
Alternative Names: C-012Latest Information Update: 27 Feb 2019
Price :
$50
*
At a glance
- Originator Curatis; Ygraine Therapeutics
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 27 Feb 2019 Discontinued - Phase-II for Migraine in United Kingdom (unspecified route)
- 15 Feb 2016 Phase-II clinical trials in Migraine in United Kingdom (unspecified route)